Abstract Several mitogens such as vascular endothelial growth factor (VEGF) have been implicated in mammalian vascular proliferation and repair. However, the molecular mediators of human blood-nerve barrier (BNB) development and specialization are unknown. Primary human endoneurial endothelial cells (pHEndECs) were expanded in vitro and specific mitogen receptors detected by western blot. pHEndECs were cultured with basal medium containing different mitogen concentrations with or without heparin. Nonradioactive cell proliferation, Matrigel TM
Introduction
The restricted internal microenvironment of the peripheral nerve endoneurium (which contains myelinated and unmyelinated axons responsible for action potential transmission to and from the central nervous system) is regulated by specialized tight junction-forming microvascular endoneurial endothelial cells that restrict the passive diffusion of solutes, macromolecules, leukocytes, and microbes from the blood circulation, and specialized perineurial cells that form concentric layers around the endoneurium, restricting diffusion of substances from the freely permeable epineurium into the endoneurium (Olsson 1990; Reina et al. 2000 Reina et al. , 2003 . Due to the direct interaction of endoneurial endothelial cells with circulating blood, these cells can be considered to form the blood-nerve barrier (BNB). The BNB is second only to the blood-brain barrier (BBB) in terms of restrictive capabilities in mammals (Malmgren and Olsson 1980; Poduslo et al. 1994; Allt and Lawrenson 2000) .
Very little is known about human BNB development, maturation and response to injury. Functional and biochemical changes may occur at the human BNB during normal development and in certain neuropathies (Pummi et al. 2004; Poduslo et al. 1988; Kanda et al. 2004) . BNB studies in animals provide insights that may be relevant to humans (Poduslo et al. 1994; Allt and Lawrenson 2000; Orte et al. 1999; Hirakawa et al. 2003; Olsson 1971; Smith et al. 2001) . However, there are phenotypic and functional differences between vascular endothelial cells from different species, endothelial cells from different tissues within the same species and macrovascular and microvascular endothelial cells within the same tissue (Aird 2007a, b; Bell and Weddell 1984a, b; Allt and Lawrenson 2000; Orte et al. 1999; Sano et al. 2007; Reina et al. 2000; Man et al. 2008; Murphy et al. 1998; Latker et al. 1987) . Endothelial cell differentiation is dependent on its specialized tissue microenvironment and function. These observations are evolutionally conserved down to invertebrates such as the hagfish (Yano et al. 2007) . In order to fully understand the possible determinants and signaling pathways responsible for human BNB development and response to injury in vivo, in vitro studies using human BNB-forming endothelial cells can provide important insights.
Studies on the BBB and other vascular barriers in humans and other species have resulted in extensive knowledge on the mediators and mechanisms of endothelial cell proliferation and specialization. Extensive studies evaluating mammalian central nervous system vascular responses to external insult provide clues that may be relevant to the human BNB (Krizanac-Bengez et al. 2004; Marchi et al. 2010; Arai et al. 2009; Guo and Lo 2009; Al Ahmad et al. 2009; Stonestreet et al. 2000; Zheng and Yenari 2004; Engelhardt and Ransohoff 2005; Man et al. 2007 ). Molecules such as vascular endothelial growth factor (VEGF) (Shibuya 2008 (Shibuya , 2009 Galvan et al. 2006; Sun et al. 2003; Wang et al. 2007; Tang et al. 2009 ), basic fibroblast growth factor (bFGF) (Sobue et al. 1999; Bendfeldt et al. 2007) , glial cell-derived neurotrophic factor (GDNF) (Utsumi et al. 2000) , transforming growth factor beta-1 (TGF-b1) (Garcia et al. 2004) , and steroids, e.g., dexamethasone and hydrocortisone (Sadowska et al. 2010; Stonestreet et al. 2000; Förster et al. 2005; Weidenfeller et al. 2005) have been implicated in these biologic processes, through defined or emerging signaling pathways (Schlessinger 2004; Takahashi 2001; Wakefield and Roberts 2002; Shabb 2001) .
We recently demonstrated an important role for GDNF in restoring the restrictive barrier characteristics of the human BNB in vitro following serum withdrawal (mimicking diffuse endothelial cell injury) via RET-tyrosine kinase-dependent signaling pathways (Yosef and Ubogu 2012) . Although GDNF was the most efficacious mitogen tested, TGF-b1, bFGF, hydrocortisone and cyclic adenosine monophosphate/ protein kinase A signaling pathways provided some redundancy in vitro. VEGF has been shown to alter tight junction protein expression by peripheral nerve microvascular cells (PnMECs) following exposure to advanced glycation endproducts (mimicking diabetic conditions) in vitro (Shimizu et al. 2011b) . Similarly, growth factors expressed by immortalized human pericyte cell lines, bFGF, GDNF, and hydrocortisone have been shown to enhance claudin-5 expression by primary or immortalized PnMECs determined by western blot within 48 h of culture, suggesting roles in promoting tight junction formation in vitro (Kashiwamura et al. 2011; Shimizu et al. 2011a Shimizu et al. , 2012 .
Despite these early advances in understanding human BNB biology supported by the recent isolation of primary human endoneurial endothelial cells (pHEndECs) and PnMECs, and their stable immortalization which has resulted in established cell lines (Yosef and Ubogu 2013; Abe et al. 2012) , the full repertoire of mitogens, co-factors and growth factor receptors required for pHEndEC proliferation, angiogenesis and response to direct trauma are currently unknown. This study demonstrates an important role for physiologic concentrations of VEGF in these biological processes at the human BNB in vitro.
Materials and Methods

Antibody and Reagents
Mouse monoclonal anti-human VEGFR2 IgG1 (clone A3) and anti-human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) IgG1 (clone 0411); polyclonal rabbit anti-human FGFR1 IgG (C-15), anti-human GFRa1 IgG (H-70), antihuman glucocorticoid receptor (GR) IgG (H-300), antihuman TGFbRI IgG (V-22), and anti-human TGFbRII IgG (L-21) were purchased from Santa Cruz Biotechnology (Santa Cruz, California, USA). Horseradish peroxidaseconjugated AffiniPure polyclonal goat anti-mouse and goat anti-rabbit IgG (H?L) antibodies were purchased from Jackson ImmuoResearch Laboratories (West Grove, Pennsylvania, USA). Recombinant human VEGF-A polypeptide 165 amino acid variant (VEGF-A 165 ), GDNF, bFGF, and TGF-b1 were purchased from PeproTech (Rocky Hill, New Jersey, USA). Hydrocortisone and heparin sodium salt (derived from porcine intestinal mucosa) were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). The nonradioactive tetrazolium salt WST-1 (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) was purchased from Roche Applied Sciences (Indianapolis, Indiana, USA). Matrigel TM Basement Membrane Matrix, derived from Engelbreth-Holm-Swarm Mouse Tumor, was purchased from BD Biosciences (Bedford, Massachusetts, USA).
Primary Human Endoneurial Endothelial Cell (pHEndEC) Isolation and Culture
The work described was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki), conforming to the Uniform Requirements for manuscripts submitted to Biomedical journals. An exemption from the Baylor College of Medicine Institutional Review Board (protocol number H-22347) was obtained to harvest endothelial cells from recently decedent individuals undergoing routine medical autopsy. pHEndECs were isolated, purified, and characterized as previously described (Yosef et al. 2010 ) and expanded by culture on rat tail collagen (RTC)-coated Corning CellBIND Ò tissue culture plates in regular growth medium. The cells were cultured at 37°C in a humidified atmosphere with 95 % air/ 5 % CO 2 in an incubator, as previously described (Yosef et al. 2010) , and passaged at 80-90 % confluence. Cultures from passages 6-8 were used for subsequent studies.
Western Blot Analysis
Total cellular (cytoplasmic and membrane) proteins were extracted from proliferating pHEndEC, simian virus 40 large-T antigen (SV40-LTA) immortalized human endoneurial endothelial cell (THEndEC, passage 20) and SV40-LTA immortalized human brain microvascular endothelial cell (THBMEC: kind gift from Dr. Monique Stins, passage 20) cultures grown to near-confluence in 75 cm 2 Corning CellBIND Ò tissue culture flasks, as previously published Ubogu 2012, 2013) . Protein extracts were quantified using the Bradford Coomassie assay and stored at -80°C. Equal amounts of protein (4 lg) were denatured, reduced, and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; 10 % slab gel) using the Bio-Rad MiniProtean III Apparatus (Hercules, CA, USA), then electrotransfered to polyvinylidene fluoride membranes in transfer buffer using the Bio-Rad Trans-Blot Apparatus, according to manufacturer instructions.
Membranes were blocked with 5 % non-fat milk or 5 % goat serum in Tris buffered saline ?0.05 % Tween-20 (TBS-T) for 1 h at RT, followed by incubation with primary antibodies diluted in TBS-T containing 1 % non-fat milk or 1-5 % goat serum overnight at 4°C (final concentration 0.4 lg/mL for GFRa1, TGFbRI, TGFbRII, and FGFR1; 1 lg/mL for GAPDH, VEGFR2, and GR). Following several washes, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies diluted in TBS-T/1 % non-fat milk or TBS-T/1-5 % goat serum (1:10,000 dilution) for 1 h at RT, washed as above, treated with pierce enhanced chemiluminescence western blotting substrate plus detection reagents (Thermo Fisher Scientific, Rockford, Illinois, USA) and visualized by generating autoradiographs following film exposure from 1 min to 1 h using an SRX-101A film processor (Konica Minolta, Tokyo, Japan).
Digital autoradiograph images were taken using an AlphaImager HP image documentation system (ProteinSimple, Santa Clara, California, USA) attached to a Sony ICX267AL 1.39 Megapixel CCD camera, as previously described. Molecular weight markers confirmed protein size.
pHEndEC Proliferation Assay
Freshly passaged pHEndECs were seeded at 5,000 cells per well into flat-bottom 96 well CellBIND Ò microplates in basal culture medium [RPMI-1640 medium (Invitrogen, Carlsbad, California, USA) containing 10 % NuSerum (BD Biosciences; Bedford, Massachusetts, USA), 10 % fetal bovine serum (PAA Laboratories, New Bedford, Massachusetts, USA), 1X penicillin-streptomycin (Mediatech Inc., Herndon, VA, USA), 1X vitamin solution, 1X nonessential amino acid solution, 2 mM L-glutamine, 1 nM sodium pyruvate, 10 mM HEPES buffer (all from Invitrogen)], with or without 25 U/mL heparin. Basal culture medium consists of regular growth medium without added growth supplements (Yosef et al. 2010 ). The cells were treated with VEGF-A 165 (0.1-100 ng/mL), bFGF (0.1-500 ng/mL), TGF-b1 (0.1-500 ng/mL), GDNF (0.1-100 ng/mL), and hydrocortisone (100-5,000 nM), to a total volume of 100 lL per well, in triplicate. Proliferation relative to basal conditions without added growth factors was quantified by absorbance after 48 h (during pHEndEC linear growth phase) using the sensitive non-radioactive tetrazolium salt, WST-1, detected with a FLUOstar Optima microplate reader (BMG Labtech, Durham, North Carolina, USA) 4 h after adding 10 lL of WST-1 per well, as previously published (Yosef et al. 2010) . Wells containing basal culture medium alone were used for background determination. The optical density (O.D.) is linearly proportional to the number of metabolically active cells for the range used. The percentage increase in proliferation over basal growth for each concentration of mitogen tested was calculated as follows:
pHEndEC Angiogenesis Assay pHEndEC angiogenesis under the influence of exogenous growth factors was studied using the 4 h Matrigel TM assay, as previously described (Yosef et al. 2010) . Freshly passaged pHEndECs were seeded at 12,500 cells/cm 2 in basal culture medium containing VEGF-A 165 (0.1-100 ng/mL), bFGF (0.1-500 ng/mL), hydrocortisone (10-5,000 nM), GDNF (1 ng/mL), and TGF-b1 (0.1 ng/mL) onto 12 well Corning CellBIND Ò tissue culture plates coated with 50 lL/cm 2 of Matrigel TM in RPMI-1640 medium with and without 25 U/mL Cell Mol Neurobiol (2013) 33:789-801 791 heparin. Plates were maintained at 37°C in a humidified atmosphere with 95 % air/5 % CO 2 in an incubator for 4 h. The mean number and total length of microvessels formed for each concentration of mitogen tested was determined by taking digital phase contrast photomicrographs of each well using an Axiocam MRc 5 digital camera attached to an Axiovert 40 Inverted Microscope (Carl Zeiss Inc. Thornwood, NY, USA) precalibrated with an S8 micrometer scale (Electron Microscopy Sciences, Hatfield, PA, USA). These parameters were quantified in triplicate using the Zeiss AxioVision software, and compared to angiogenesis in basal medium.
pHEndEC Wound Healing Assay pHEndECs were grown to [90 % confluence on RTCcoated 12 well CellBIND Ò tissue culture plates in regular growth medium. A sterile micropipette injury (one vertical and three horizontal lines) was performed in each well using an autoclaved plastic 1,000 lL micropipette tip (Lee and Kay 2006) . Cellular debris was washed away twice by gentle aspiration after adding 500 lL of basal medium per well. The endothelial cell monolayers were treated with VEGF-A 165 (1-100 ng/mL), bFGF (1-500 ng/mL), hydrocortisone (100-1,000 nM), 1 ng/mL GDNF or 0.1 ng/mL TGF-b1 in basal medium with or without 25 U/mL heparin, to a total volume of 500 lL per well. The rate of wound recovery over 30 h was quantified using computer-assisted measurements of sequential phase contrast digital photomicrographs of the same 10 non-overlapping regions per well. Images were taken hourly and analyzed using the Axiocam MRc5 and Zeiss Axiovision software. The average rate of pHEndEC monolayer wound recovery (in lm/h) was compared to recovery without added growth factors, heparin or both.
Statistical Analyses
Statistical analyses (unpaired one or two-tailed Student's t test or analysis of variance) were performed using JMP 
Results
Determination of pHEndEC Growth Factor Receptor Expression
Using THBMECs as a positive control, we demonstrated expression of VEGFR2, FGFR1, TGFbRI and TGFbRII, GFRa1 and GR, the receptors for VEGF, bFGF, TGF-b1, GDNF, and hydrocortisone respectively, on proliferating pHEndECs (Fig. 1) . We had previously demonstrated GFRa1 expression on pHEndECs by western blot and immunocytochemistry, with increased receptor expression following diffuse endothelial cell injury mediated by serum withdrawal (Yosef and Ubogu 2012) . GR expression had been previously demonstrated on immortalized PnMECs (Kashiwamura et al. 2011 ). Interestingly, VEGFR2 was not detected on contact-inhibited pHEndEC cultures by western blot (data not shown). These receptors were also expressed by THEndECs, implying retention of these growth factor receptors with stable transfection and immortalization, as shown on Fig. 1 . These data demonstrate that pHEndECs are capable of directly responding to the above mitogens under different experimental conditions in vitro, providing rationale to further determine their roles in BNB endothelial cell proliferation, angiogenesis and wound healing.
VEGF Potently Induces pHEndEC Proliferation
In Vitro, in the Presence of Heparin Vascular endothelial growth factor was the most potent inducer of pHEndEC proliferation in vitro 48 h after seeding, with a mean maximum increase in proliferation relative to basal growth of 110 ± 2.4 % at a concentration of 50 ng/mL (1.31 nM), in the presence of heparin. Proliferation rose steeply between 1 ng/mL (23.2 ± 1.9 %) Fig. 1 pHEndEC growth factor receptor expression. Representative composite digital autoradiographs following Western blot to detect specific growth factor receptors expressed by proliferating nearconfluent pHEndECs (p-BNB), THEndECs (i-BNB), and THBMECs (i-BBB) are shown, with GAPDH serving as an internal protein loading control. Protein extracts from three isolates are displayed on the same autoradiograph to demonstrate similarity in growth factor receptor expression by these cell lines. Molecular weights of the detected proteins are shown on the left and 10 ng/mL (108.8 ± 2.7 %) and dropped between 50 and 100 ng/mL (Fig. 2) . Hydrocortisone (mean maximum increase in proliferation of 71.5 ± 3.0 % at a concentration of 2,500 nM) and bFGF (66.0 ± 2.3 % at 100 ng/mL [5.81 nM]) demonstrated an equivalent magnitude of effect on pHEndEC proliferation, with bFGF being similarly potent at a lower molar concentration (Fig. 2) . Hydrocortisone-induced proliferation showed very little change between 100 and 2,500 nM, while bFGF-induced proliferation was relatively stable with some variation between 1 and 100 ng/mL, as shown on Fig. 2 . GDNF had a minor effect on proliferation, with a mean maximum increase in proliferation of 15.8 ± 2.1 % at a concentration of 1 ng/ mL (0.03 nM) while TGF-b1 inhibited pHEndEC proliferation, with a maximum reduction in proliferation compared to basal growth of 28.0 ± 4.4 % at a concentration of 1 ng/mL (0.04 nM) that remained unchanged up to a concentration of 500 ng/mL (Fig. 2) .
Heparin (25 U/mL) had a positive effect on pHEndEC proliferation induced by VEGF, bFGF, and hydrocortisone ( Fig. 3a) , with a mean percentage reduction in proliferation of 53.6, 48.4, and 28.1 % observed without heparin at maximum growth-inducing concentrations, respectively. GDNF inhibited pHEndEC proliferation in the absence of heparin, with a mean 150 % reduction in proliferation observed at 1 ng/mL (Fig. 3a) . TGF-b1 more effectively inhibited pHEndEC proliferation in the absence of heparin, with inhibition of 28.2 ± 1.1 % observed at 0.1 ng/mL (0.004 nM, Fig. 3a ) that remained relatively unchanged between 0.1 and 100 ng/mL, with a gradual reduction in proliferation at higher concentrations that was maximum (51.7 ± 1.3 %) at a concentration of 500 ng/mL (20 nM), as shown in Fig. 3b . The reduction in proliferation seen at 500 ng/mL was statistically significant relative to the reduction observed between 0.1 and 100 ng/mL (p values 0.00008, 0.037, 0.004, and 0.0003, respectively).
These data suggest that VEGF is a potent inducer of human BNB endothelial cell proliferation in vitro, with heparin serving as an important co-factor. The VEGF effect on proliferation has a narrow dose response range between 10 and 50 ng/mL. There is redundancy in human BNB endothelial cell proliferation in vitro, as hydrocortisone and bFGF were capable of inducing cellular proliferation although these mitogens were less efficient and required higher molar concentrations. However, they possessed broader ''therapeutic windows'' than VEGF [five-fold broader with hydrocortisone and 40-fold with bFGF]. TGF-b1 inhibited human BNB endothelial cell proliferation in vitro with potency enhanced in the absence of heparin that was sustained at higher concentrations. GDNF mildly induced human BNB endothelial cell proliferation in vitro in the presence of heparin, but became an inhibitor of endothelial cell growth when heparin was absent.
VEGF Potently Induces pHEndEC Angiogenesis
In Vitro VEGF at a concentration of 0.1 ng/mL (2.6 pM) was the most effective inducer of pHEndEC angiogenesis in vitro, defined as the mean number of microvessels/field (Fig. 4a ) and mean total capillary length/field (Fig. 4b) under the influence of Matrigel TM . This concentration of VEGF induced a mean of 19.0 (±0.6) microvessels/field, compared to 6.3 ± 1.2 microvessels/field with basal medium that lacked exogenous mitogens. Thus, VEGF induced a mean 3.0-fold increase in the number of microvessels on Matrigel TM Basement Membrane Matrix over basal conditions. VEGF was less potent at 10 ng/mL (12.3 ± 1.8 microvessels/field) and lost its effect on angiogenesis by 100 ng/mL. bFGF was as effective as VEGF in inducing pHEndEC angiogenesis, with a mean of 19.0 (±4.5) microvessels/field at a concentration of 10 ng/mL (581 pM), with a significant increase compared to 0.1 ng/mL. There was loss of efficacy in bFGF-induced angiogenesis at a concentration of 500 ng/mL (10.3 ± 1.5 microvessels/field). GDNF (1 ng/mL, 3.3 pM) and hydrocortisone (10 nM) had small, but significant effects on pHEndEC angiogenesis (mean number of microvessels/field of 10.7 ± 2.2 and 11.0 ± 2.5, respectively) compared to basal conditions, while TGF-b1 had no significant effect on the number of induced microvessels, as shown in Fig. 4a .
Similarly, VEGF 0.1 ng/mL (2.6 pM) induced a maximum mean total capillary length of 5,490 ± 405 lm/field, compared to 1,400 ± 655 lm/field under basal conditions, Fig. 3 Effect of heparin on mitogen-induced pHEndEC proliferation. The bar histographs depict pHEndEC proliferation as a percentage change of basal proliferation comparing maximum effective proliferative mitogen concentrations under with influence of heparin (25 U/mL), with growth without added heparin. Statistically significant reductions in pHEndEC proliferation are observed for all mitogens tested in the absence of heparin, with GDNF 1 ng/mL demonstrating a reversal in effect at 1 ng/mL and TGF-b1 demonstrating potent inhibitory effects at 0.1 ng/mL (a). Further analyses of the TGF-b1-mediated effects on pHEndEC proliferation demonstrates significantly increased inhibition in the absence of heparin that is relatively stable between 1 and 100 ng/mL, with a more significant increase observed at 500 ng/mL (b). *p \ 0.05 relative to basal proliferation. Error bars represent standard errors of the means, N = 3 representing a mean 3.9-fold increase in total capillary length. There was a gradual reduction in VEGF-induced angiogenesis based on this parameter at higher concentrations as previously described with the number of microvessels formed. As described above, bFGF 10 ng/mL (581 pM) had a similar angiogenic effect to VEGF (4,780 ± 1,710 lm/field), albeit at a 223-fold higher molar concentration, as shown in Fig. 4b . The bFGF dose-effect relationship on the mean total capillary length between 0.1 and 500 ng/mL is similar to that described previously. GDNF (1 ng/mL, 3.3 pM) and hydrocortisone (10 nM) had significant effects on the mean total induced pHEndEC capillary length (2,500 ± 390 lm/field and 3,060 ± 758 lm/field, respectively) compared to basal conditions, while TGF-b1 had no significant effect on mean total capillary length, as shown in Fig. 4b . Matrigel TM -supported angiogenesis did not occur at 4 h with heparin absent in these series of experiments, with clusters of cells seen without significant microvessel formation.
These data suggest that VEGF, in picomolar concentrations, potently induced human BNB angiogenesis on a Matrigel TM Basement Membrane Matrix in vitro. This process was redundant, as bFGF, hydrocortisone, and GDNF (in descending order of effect) were capable of inducing pHEndEC angiogenesis, although less efficiently than VEGF or at much higher molar concentrations. TGF-b1 did not have a significant effect on human BNB angiogenesis in vitro relative to basal conditions without added mitogens. Consecutive time-lapse phase contrast photomicrographs demonstrated that pHEndEC monolayer wound healing following sterile micropipette injury in the presence of heparin occurred in three phases; 0-4 h: no appreciable change in wound size, 4-18 h: endothelial cell migration across the wound with reduction in wound width, and 18-30 h: endothelial cell proliferation. Under basal conditions without exogenous mitogens, pHEndEC migration across the wound occurred at a mean rate of 42.9 ± 3.0 lm/h. 10 ng/mL VEGF (0.26 nM) was most effective at inducing cellular migration across the wound 4-18 h after injury, at a rate of 54.4 ± 2.8 lm/h, representing a 26.8 % mean increase in the rate of cellular migration during wound closure in vitro, as shown in Fig. 5 . There was a reduction in the rate of VEGF-mediated cellular migration observed with 100 ng/mL (2.62 nM): 50.8 ± 2.5 lm/h, compared to 10 ng/mL VEGF. 10 ng/mL bFGF (581 pM; 52.5 ± 2.2 lm/h) and 100 nM hydrocortisone (49.9 ± 3.6 lm/h) were the only other mitogens that significantly enhanced the mean rate pHEndEC migration across the wound during this healing phase in vitro (Fig. 5 ). Higher concentrations of these mitogens were less effective or significantly inhibited cellular migration during wound healing relative to basal conditions, as seen with 1,000 nM hydrocortisone and 500 ng/mL bFGF. GDNF (1 ng/mL; 33 pM) had no appreciable effect on pHEndEC migration, while TGF-b1 (0.1 ng/ mL; 4 pM) significantly inhibited cellular migration (35.6 ± 3.3 lm/h) compared to basal rates without exogenous mitogens, as shown in Fig. 5 . In the absence of heparin or VEGF, the mean rate of cellular migration across the wound was 12.47 ± 3.2 lm/ h, representing a 71.9 % mean reduction relative to basal migration under the influence of 25 U/mL heparin. VEGF 10 and 100 mg/mL significantly increased cellular migration with heparin absent (38.3 ± 3.9 and 29.1 ± 3.2 lm/h, respectively); however, these rates remained significantly below endogenous pHEndEC migration across the wound 4-18 h after injury under the influence of heparin. Interestingly, in the presence of heparin, only VEGF 10 and 100 ng/mL were able to complete the pHEndEC wound healing process by 30 h following sterile micropipette injury via increased cellular proliferation (Fig. 6) . No significant change in the mean residual wound widths following initial cellular migration was observed between 18 and 30 h for the other mitogens tested (data not shown). In vitro pHEndEC wound healing assay. The bar histographs demonstrate the mean recovery rate (in lm/h) of confluent cultured pHEndEC monolayers between 4 and 18 h following sterile micropipette injury, comparing different concentrations of mitogens to basal recovery rates without added mitogens in the presence of 25 U/mL heparin. This process is mediated by cellular migration across the wound. VEGF induces the most rapid recovery rate, maximal at 10 ng/mL that persisted (albeit less effective) at 100 ng/mL. Less significant effects are seen with bFGF (10 ng/mL) and hydrocortisone (100 nM), the only other mitogens that induced more rapid mean recovery rates compared to basal conditions. GDNF (1 ng/mL) demonstrates no appreciable effect on wound healing, while TGF-b1 (0.1 ng/mL) demonstrates an inhibitory effect on pHEndEC wound healing in these series of experiments. Hourly recovery rates from 10 non-overlapping regions per tested condition were averaged in these series of experiments. *p value \ 0.05 relative to basal recovery. Error bars indicate standard errors of the mean These studies demonstrate an important role for exogenous heparin and VEGF, in picomolar to low nanomolar concentrations, in facilitating complete pHEndEC monolayer wound healing following sterile micropipette injury within 30 h in vitro.
Discussion
This study demonstrates an important role for VEGF in human BNB endothelial cell proliferation, angiogenesis, and monolayer wound healing following direct trauma in vitro, implying that VEGF may be a key mediator of human endoneurial microvessel formation during development and recovery following traumatic injury. pHEndECs express VEGFR2, implying a direct effect of exogenous VEGF on these cells during proliferation, angiogenesis, and recovery from direct trauma. Heparin is an important cofactor for the observed VEGF-mediated mitogenic effects, suggesting a direct role in facilitating functional interactions between VEGF-A 165 and VEGFR2, as suggested with human umbilical endothelial cells (Ashikari-Hada et al. 2005) . PnMECs have been shown to express VEGF in vitro (Shimizu et al. 2011b) , implying that basal pHEndEC cellular proliferation, angiogenesis, and wound healing may be associated with endogenous VEGF production. However, exogenous VEGF in picomolar or low nanomolar concentrations (with a well-defined ''dose-response curve'') robustly facilitated these biological processes with human BNB-forming microvascular endothelial cells in vitro, suggesting that other resident peripheral nerve endoneurial cells such as pericytes and Schwann cells may contribute to BNB microvessel development and recovery from injury. This is consistent with the concept that VEGF functions as a paracrine mediator based on observations between neoplastic cells and nearby endothelial cells during tumor growth and metastatic spread (Roskoski 2007) .
In vivo, exogenous VEGF administered via gene transfer using a plasmid DNA encoding human VEGF-1 or VEGF-2 has been shown to induce vascular proliferation in the sciatic nerves of streptozosin-induced diabetic rats and alloxan-induced diabetic rabbits, associated with disease reversal (Schratzberger et al. 2001) . A double-blinded clinical trial of intramuscular VEGF gene transfer in human diabetic polyneuropathy demonstrated improved sensory perception and less nociception, without significant change in nerve conduction potentials (Ropper et al. 2009 ). These observations support the notion that VEGF is a potent vascular mitogen in peripheral nerves, required for neovascularization and axonal regeneration following injury (Pola et al. 2004) . Our study, however, demonstrated some redundancy in VEGF-mediated human BNB endothelial cell proliferation, angiogenesis and wound healing in vitro. Hydrocortisone and bFGF were capable of inducing pHEndEC proliferation and migration across a sterile wound in the presence of heparin, although less efficiently than VEGF, and bFGF was equally effective at inducing BNB angiogenesis in vitro on a Matrigel TM Basement Membrane Matrix, although at a higher molar concentration than VEGF. Interestingly, only VEGF was capable of complete wound healing within 30 h following sterile monolayer injury via cellular proliferation. This implies a non-redundant role for VEGF during the final phase of human BNB endothelial cell wound recovery following direct trauma in vitro. We observed that TGF-b1 inhibited pHEndEC proliferation in vitro as well as migration during the second phase of recovery from sterile micropipette injury, with no appreciable effect on angiogenesis. These observations are consistent with its role as a paracrine inhibitor of epithelial and endothelial cell growth in normal tissues (Wakefield and Roberts 2002) . Signaling is known to occur via heterotetrameric complex of two transmembrane receptor serine/threonine kinases, consisting of a type II ligand binding receptor (TGFbRII) and a type I signaling receptor (TGFbRI) (Wakefield and Roberts 2002) . pHEndECs express both receptors in vitro (Fig. 1) , implying a direct inhibitory effect of TGF-b1 on these biological processes. The anti-proliferative effect of TGF-b1 on pHEndECs was inhibited by heparin, as observed in rat models of liver fibrosis and acute lung injury (Lee et al. 2011; Mu et al. 2012) . TGF-b1 is known to bind heparin with high affinity (McCaffrey et al. 1992; Rider 2006) , with a study suggesting a direct role for heparin in potentiating the biologic activity of TGF-b1-mediated inhibition of rat and bovine aortic smooth muscle cell proliferation in vitro. However, this effect was not seen in human saphenous vein smooth muscle cells in vitro (McCaffrey et al. 1989) , suggesting differential mechanistic effects of TGF-b1-heparin interactions dependent on species and tissue origin.
GDNF demonstrated a small effect on pHEndEC proliferation and angiogenesis in vitro, with no significant effect on in vitro BNB monolayer wound healing following direct trauma in the presence of heparin. GDNF demonstrated inhibitory effects on pHEndEC proliferation with heparin absent. GDNF has been shown to bind heparin with high affinity (Rider 2006) , suggesting a possible role in facilitating GDNF-GFRa1-RET Tyrosine kinase signaling. The GDNF effect described above is in contrast to its potent ability to restore in vitro BNB restrictive barrier characteristics following non-traumatic diffuse endothelial injury mediated by serum withdrawal. GDNF, in picomolar concentrations, induced cytoskeletal modifications with F-actin filament relocation from within the cytoplasm toward cell membranes associated with more continuous intercellular contacts that provided the scaffold for adherens and tight junction formation within 48 h, associated with increased transendothelial electrical resistance and reduced solute permeability to high molecular weight fluoresceinated dextran, back to pre-injury levels (Yosef and Ubogu 2012) .
Sterile micropipette injury differs from endothelial cell injury mediated by serum withdrawal, as there is significant endothelial cell loss following direct trauma (Lee and Kay 2006) , in contrast to endothelial cell detachment from neighboring cells with residual focal intercellular contacts secondary to cytoplasmic retraction observed following serum withdrawal in vitro (Yosef and Ubogu 2012) . Following traumatic in vitro BNB injury, endothelial cell migration across the wound (4-18 h) followed by proliferation (18-30 h) was necessary for complete recovery. Under the influence of GDNF, surviving endothelial cells at the edge of the wound were observed to send cytoplasmic processes across the wound based on time-lapsed phase contrast micrographs, with minimal effect on reducing wound size compared to basal conditions. Taken with our recently published study, we hypothesize that GDNF may be essential for inducing cytoskeletal changes necessary for the formation of restrictive intercellular junctions following human BNB endothelial cell proliferation and contact inhibition in vitro.
Conclusions
This study demonstrates an important role for VEGF in human BNB endothelial cell proliferation, angiogenesis, and traumatic wound healing in vitro, enhanced by heparin. The VEGF-mediated effects are dose-dependent, with a characteristic ''inverted U'' shaped curve with well-defined dose-effect ''therapeutic windows'' in the picomolar or low nanomolar range. This study suggests important physiologic roles for VEGF in human BNB microvascular development and recovery following injury in vivo. pHEndECs express VEGFR2, implying a direct means by which exogenous VEGF can facilitate these biologic effects. Further work is required to determine the key signaling pathways and downstream regulators in human peripheral nerves as a means to further understand human peripheral nerve microvascular development and BNB formation during embryogenesis and early postnatal life, as well as the reparative processes that occur as a consequence of direct traumatic injury or peripheral neuropathies associated with pathologic microvascular alterations such as diabetes mellitus.
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